by Dementia Treatment Market – Snapshot
The dementia associated with Alzheimer’s disease market is expected to reach a market value of about US$ 6,936.8 Mn by the end of 2026, expanding at a single digit CAGR during the forecast period. Rise in R&D expenditure, increased prevalence of Alzheimer’s across the globe, increased geriatric population, rise in awareness regarding neurodegenerative diseases in developing countries, and rich pipeline of innovative treatment options are expected to boost the dementia associated with Alzheimer’s disease market during the forecast period. Moreover, increasing research and development activities in disease modifying drugs and surge in investment by key players in the clinical studies of advanced treatment options are expected to propel the dementia associated with Alzheimer’s disease market during the forecast period. However, the high cost of advanced treatments and severe side-effects associated with certain treatments are expected to hamper the dementia associated with Alzheimer’s disease market.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111971
The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market, in terms of value, as it is first line of treatment for AD and most widely prescribed drug for the treatment of AD. This segment is also expected to expand at a significant CAGR, owing to its effectiveness in the treatment of mild to severe dementia. Currently, there is no disease modifying treatment available for Alzheimer’s, and the only approved treatment for the symptomatic relief of AD are cholinesterase inhibitors (Aricept, and memantine. The memantine segment is expected to expand at a notable CAGR, owing to its ability to treat moderate to severe AD and its suitability in cholinergic/ cholinesterase (chE) inhibitors intolerant patients suffering from AD.
In terms of distribution channel, the dementia associated with Alzheimer’s disease market has been segregated into hospital pharmacies, retail, and online sales. The hospital pharmacies segment held a major share of the market in 2017, followed by retail. The hospital pharmacies segment is expected to maintain its market share during forecast period due to availability of cost-effective medications for the treatment of AD. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of drugs at home at a discounted price and long-term treatment required for the treatment of Alzheimer’s disease.
In terms of geography, the dementia associated with Alzheimer’s disease market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the dementia associated with Alzheimer’s disease market owing to high awareness regarding Alzheimer’s disease in the U.S. and increased prevalence of AD in the region. According to the World Alzheimer’s Report, Alzheimer’s is the sixth-leading cause of death in the U.S. and currently, more than 5 million Americans are living with Alzheimer’s. Rising incidence of Alzheimer’s in elderly age group and demand for advanced therapies and disease modifying drugs is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure and rising awareness regarding Alzheimer’s in countries such as China and India.
Major players operating in the dementia associated with Alzheimer’s disease market include Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc., Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.
Dementia Associated with Alzheimer’s Disease Market – Snapshot
Alzheimer’s is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer’s disease accounts for 60-80% of dementia cases. Dementia associated with Alzheimer’s disease is not a normal part of aging. The greatest known risk factor is increasing age, and the majority of people with Alzheimer’s are 65 and older. But dementia associated with Alzheimer’s disease is not just a disease of old age. Alzheimer’s worsens over time. Alzheimer’s is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer’s, individuals lose the ability to carry on a conversation and respond to their environment. Alzheimer’s is the sixth leading cause of death in the United States. On average, a person with Alzheimer’s lives four to eight years after diagnosis, but can live as long as 20 years, depending on other factors.
Dementia associated with Alzheimer’s disease has no current cure, but treatments for symptoms are available and research continues. Although current Alzheimer’s treatments cannot stop Alzheimer’s from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life for those with dementia associated with Alzheimer’s disease and their caregivers. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing. The most common early symptom of Alzheimer’s is difficulty remembering newly learned information.
The most common early symptom of Alzheimer’s is difficulty remembering newly learned information because Alzheimer’s changes typically begin in the part of the brain that affects learning. As Alzheimer’s advances through the brain it leads to increasingly severe symptoms, including disorientation, mood and behavior changes. Signs of dementia associated with Alzheimer’s disease may be more obvious to family members or friends. Anyone experiencing dementia-like symptoms should see a doctor as soon as possible.
The global dementia associated with Alzheimer’s disease market has been segmented as below:
Drug Class
- Cholinergic/ Cholinesterase (ChE) Inhibitors
- Memantine
- Combined Drug (Memantine & Donepezil) and Others
Distribution Channel
- Hospital Pharmacies
- Retail
- Online Sales
Region
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- GCC Countries
- Rest of Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111971/2900
